InsiderSignal.AI

InsiderSignal.ai

AGIO - Agios Pharmaceuticals, Inc.

Insider Sale by Jones Cecilia (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Jones Cecilia, serving as CFO at Agios Pharmaceuticals, Inc. (AGIO), sold 3,141 shares at $34.71 per share, for a total transaction value of $109,024.00. Following this transaction, Jones Cecilia now holds 54,998 shares of AGIO.

This sale represents a 5.00% decrease in Jones Cecilia's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, April 2, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 6, 2026, 4 days after the trade was made.

Agios Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Jones Cecilia

Jones Cecilia

CFO

Cecilia Jones is the Chief Financial Officer (CFO) at Agios Pharmaceuticals, Inc. (AGIO), a biopharmaceutical company focused on rare diseases, where she joined in September 2022, replacing Jonathan Biller.[[1]](https://www.mmm-online.com/home/channel/people-moves/agios-names-cecilia-jones-as-cfo/)[[2]](https://www.agios.com/about-us/leadership/cecilia-jones%EF%BF%BC/) She recently sold 2,932 shares of AGIO stock on December 30, 2025, for approximately $79,427, following the exercise of 6,000 performance share units, and now directly owns 37,394 shares.[[3]](https://www.investing.com/news/insider-trading-news/jones-cecilia-agios-pharmaceuticals-cfo-sells-79k-in-stock-93CH-4428450) Jones brings over 20 years of financial experience in the biopharmaceutical industry.[[2]](https://www.agios.com/about-us/leadership/cecilia-jones%EF%BF%BC/) Prior to Agios, she was CFO at LogicBio, managing financial strategy, financing, business development, accounting, and investor relations. Before that, she spent over 10 years at Biogen in escalating finance roles, including Vice President of R&D, worldwide medical and business development finance, Senior Director of corporate finance, and Director of finance for emerging markets. Earlier, she served as Director of international finance at Genzyme. She holds a Licenciatura en Economia from Universidad de San Andres in Buenos Aires, Argentina, and an MBA from Harvard Business School.[[2]](https://www.agios.com/about-us/leadership/cecilia-jones%EF%BF%BC/)

View full insider profile →

Trade Price

$34.71

Quantity

3,141

Total Value

$109,024.00

Shares Owned

54,998

Trade Date

Thursday, April 2, 2026

7 days ago

SEC Filing Date

Monday, April 6, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Agios Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning AGIO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5419951

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime